NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)
New VTE Incidence ‘Significant’ After CAR T-Cell Therapy for Lymphoma
Results from an analysis of 148 patients who received CD19-directed CAR T-cell therapy for aggressive B-cell lymphomas showed that more than one in 10 patients developed new venous thromboembolism, although most patients were managed with therapeutic anticoagulation and experienced no bleeding complications.
Healio: Hematology/Oncology
